Sanofi and GlaxoSmithKline plc have announced the start of the Phase I/II trial for their adjuvanted COVID-19 vaccine – a relative latecomer to the field but which has the potential to play a central role in tackling the pandemic in 2021.
Paul Hudson, Sanofi’s CEO has dubbed the vaccine the ‘tortoise’ in the race against the speedy ‘hare’ candidates from companies...







